News & Events

AFTD CEO Discusses Wendy Williams’s FTD Diagnosis

In an interview with The Daily Beast about Wendy Williams’s recent FTD diagnosis, AFTD CEO Susan L-J Dickinson spoke about the stigma surrounding FTD and the importance of getting an…

MORE

Guest Feature: Somebody’s Sister

FTD is an aggressive disease that disrupts people’s lives and relationships, with families often unsure what they are up against at first because it isn’t widely known. As Deborah Dowdell Perry shares…

MORE

Broadcaster Wendy Williams Diagnosed with FTD

The former talk show host Wendy Williams was diagnosed with FTD last year, her care team announced in a Feb. 22 statement. “In 2023, after undergoing a battery of medical…

MORE

AFTD Volunteer Shares Father’s FTD Journey to Promote Awareness in News Interviews

AFTD volunteer Scott Oxarart raised awareness of FTD throughout Nevada in interviews aired by 2 News Nevada and KOLO News Now on February 13 and 14. A former care partner…

MORE

Transposon Announces Results from Phase 2 PSP Trial, Interim Results for Phase 2 FTD/ALS Trial

The biotechnology company Transposon Therapeutics on February 12 released final results for its phase 2 clinical trial focusing on progressive supranuclear palsy (PSP) and interim results for its phase 2…

MORE

Treat FTD Fund Grant Recipient Discusses FTD-GRN Gene Therapy in Newspaper Interview

Simon Ducharme, MD, MSc, FRCPC, of McGill University, a recent recipient of a grant through the Treat FTD Fund, discussed an experimental gene therapy for FTD-GRN in a December interview…

MORE

Viewpoints of FTD: Addressing Barriers to Diagnosis, FTD Care, and Research Participation Faced by Black/African Americans

In 2011, researchers estimated there to be 50,000-60,000 cases of FTD in the United States. Today, however, researchers believe this figure to be an undercount. One reason for this is…

MORE

FDA Grants Breakthrough Therapy Designation to Experimental FTD Therapy

The U.S. Food and Drug Administration (FDA) has granted a “breakthrough therapy designation” to latozinemab, an experimental treatment for FTD caused by a GRN genetic mutation. The drug is being…

MORE